Novavax, US Biotechnology Company, Begins Trials Coronavirus Vaccine Candidate in Australia


Phase 1 of the trial is a "randomized, observer-blinded, placebo-controlled trial" that assesses two different dosage sizes of the vaccine among healthy participants age 18 to 59, Novavax said in a press release.

"Administering our vaccine in the first participants of this clinical trial is ... bringing us one step closer toward addressing the fundamental need for a vaccine in the fight against the global COVID-19 pandemic", he said.

Novavax and CEPI said they agree on the importance of "global equitable access" to vaccines produced from their partnership.

In parallel with ramping up production at Bohumil, Erck added, Novavax will continue efforts to expand antigen capacity in the US and Asia, and will increase production of Matrix-M to match antigen capacity at multiple sites globally. These risks and uncertainties include those identified under the heading "Risk Factors" in the Novavax Annual Report on Form 10-K for the year ended December 31, 2019, as filed with the Securities and Exchange Commission (SEC) and updated by any Quarterly Report on Form 10-Q, particularly the risks inherent to developing novel vaccines. Novavax recently initiated development of NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19, with Phase 1 clinical trial results expected in July of 2020. It's not clear that any will prove safe and effective.

Glenn said in an online press conference from Novavax's Maryland headquarters, "We are producing drugs and vaccines together thinking that we will be able to show that it works and make it available to the public by the end of the year".

Animal testing suggested the vaccine is effective in low doses.

Hong Kong security law could mean 'joint' probes with mainland: parliament adviser
It called for a new law in Hong Kong to prevent and punish acts of " secession , subversion or terrorism activities". But China's latest move is likely to trigger another round of popular protest against Beijing's rule.

An organization spokesperson tells CNN Novavax expects to ship 100 million doses of the vaccine by the finish of the 12 months, and a billion doses in 2021. Moreover, if the product can beat Sanofi's flu vaccine Fluzone in the clinical trials, then it could also create greater confidence for its coronavirus vaccine.

Novavax said its acquisition of Praha is among uses to be funded by up to $388 million committed to the company by the Coalition for Epidemic Preparedness Innovations (CEPI). CanSino has moved its vaccine candidate into Phase II.

The trial began with six volunteers being injected with the potential vaccine in Melbourne on Tuesday, said Paul Griffin, infectious disease expert with Australian collaborator Nucleus Network. First, its scientists resort to genetic engineering and use insect cells to make benign copies of the characteristic spike protein of the Coronavirus. Still other candidate vaccines are more outdated, made from complete dead viruses.

Novavax adds another new kind to that list, what's called a recombinant vaccine.

"These results provide strong evidence that the vaccine candidate will be highly immunogenic in humans, leading to protection from COVID-19 and thus helping to control the spread of this disease", the assertion mentioned. But ultimately, "it looks like a virus to the immune system".